First Line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

Northwestern University will enroll approximately 30 patients per year in the FAST Uveitis Trial, for a total of 50 patients over the 2.5 year study period. This site is directed by Principal Investigator Dr. Debra Goldstein. Dr. Goldstein is a professor of Ophthalmology and Uveitis specialist at Northwestern. Dr. Goldstein will act as a co-Investigator, attend to study patients, supervise a study coorsinator and an Optometrist, along with overseeing all patient procedures throughout the trial. Dr. Goldstein will provide intellectual contributions to the study design and protocol.